查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1728151

綜合代謝組檢測市場－全球產業規模、佔有率、趨勢、機會和預測，按分析物、按疾病、按最終用途（實驗室、PoC、PoC）、按地區和競爭細分，2020 年至 2030 年

Comprehensive Metabolic Panel Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Analytes, By Disease, By End Use (Laboratory, PoC, PoC ), By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球綜合代謝組 (CMP) 檢測市值為 124.1 億美元，預計到 2030 年將達到 215.6 億美元，預測期內複合年成長率為 9.62%。 CMP 測試是一種基本的診斷工具，透過分析血糖、肝臟酵素、腎功能和電解質平衡來評估整體代謝健康。代謝和慢性疾病負擔的增加，以及全球對預防性醫療保健和早期診斷的重視，正在推動市場需求。

市場概覽
預測期 2026-2030
2024年市場規模 124.1億美元
2030年市場規模 215.6億美元
2025-2030 年複合年成長率 9.62%
成長最快的領域 糖尿病
最大的市場 北美洲

隨著世界各地的醫療保健系統擴大採用常規健康篩檢，CMP 測試正在整合到醫院、診斷實驗室和門診設施的標準診斷工作流程中。自動化實驗室系統和即時診斷設備的技術進步進一步支持了市場發展，實現了更快的周轉速度和更廣泛的可及性。隨著老齡人口的成長和患者監測需求的增加，對 CMP 檢測的需求持續上升，尤其是在慢性病管理方面。電子健康記錄 (EHR) 和基於人工智慧的工具等數位技術的整合正在增強結果解釋，有助於實現更個人化的護理。儘管存在設備成本和服務不足地區的醫療服務有限等障礙，但由於醫療保健的不斷創新和意識的不斷提高，市場前景仍然強勁。

關鍵市場促進因素

慢性和代謝性疾病盛行率上升

主要市場挑戰

先進診斷設備成本高昂

主要市場趨勢

轉向個人化和預防性醫療保健

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球綜合代謝組檢測市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依分析物（K+、Na+、Cl-、CO2、葡萄糖、尿素氮、肌酸酐、Ca++、白蛋白、總蛋白、鹼性磷酸酶、丙氨酸氨基轉移酶、天門冬胺酸氨基轉移酶、總膽紅素）
    • 依疾病（腎臟病、肝病、糖尿病、其他）
    • 依最終用途（實驗室、PoC、PoC（儀器））
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美綜合代謝組檢測市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲綜合代謝組檢測市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區綜合代謝組檢測市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲綜合代謝組檢測市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲綜合代謝組檢測市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Abbott Laboratories
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings Limited
  • Sonic Healthcare Limited
  • Unipath Specialty Laboratory Limited
  • SYNLAB International GmbH
  • ARUP Laboratories
  • Genoptix, Inc.
  • Nova Medical, Inc.
  • Mindray Medical International Limited

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 29090

The Global Comprehensive Metabolic Panel (CMP) Testing Market was valued at USD 12.41 Billion in 2024 and is projected to reach USD 21.56 Billion by 2030, expanding at a CAGR of 9.62% during the forecast period. CMP testing is a fundamental diagnostic tool used to assess overall metabolic health by analyzing blood glucose, liver enzymes, kidney function, and electrolyte balance. The rising burden of metabolic and chronic diseases, along with the global emphasis on preventive healthcare and early diagnosis, is propelling market demand.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 12.41 Billion
Market Size 2030USD 21.56 Billion
CAGR 2025-20309.62%
Fastest Growing SegmentDiabetes
Largest MarketNorth America

As healthcare systems worldwide increasingly adopt routine wellness screenings, CMP tests are being integrated into standard diagnostic workflows across hospitals, diagnostic labs, and outpatient facilities. The market is further supported by technological advancements in automated laboratory systems and point-of-care devices, enabling faster turnaround and broader accessibility. With the growing aging population and increased patient monitoring needs, demand for CMP testing continues to rise, especially in chronic disease management. Integration of digital technologies like EHRs and AI-based tools is enhancing result interpretation, contributing to more personalized care. Despite barriers such as equipment cost and limited access in underserved areas, the market outlook remains strong due to continuous healthcare innovations and rising awareness.

Key Market Drivers

Rising Prevalence of Chronic and Metabolic Disorders

The increasing global incidence of chronic and metabolic diseases is a major factor driving the demand for comprehensive metabolic panel testing. Noncommunicable diseases (NCDs), including cardiovascular conditions, cancers, chronic respiratory diseases, and diabetes, account for a substantial proportion of global mortality, with metabolic dysfunctions such as hyperglycemia, hypertension, and hyperlipidemia being core risk factors.

CMP tests are critical in detecting these underlying abnormalities by evaluating key biomarkers such as glucose, electrolytes, and liver and kidney function. A global analysis indicates that metabolic syndrome affects between 12.5% and 31.4% of the population, with higher rates in regions like the Eastern Mediterranean and the Americas. As early detection becomes integral to disease prevention and long-term health management, the role of CMP testing is expanding in both clinical and primary care settings, driving market growth.

Key Market Challenges

High Cost of Advanced Diagnostic Equipment

The cost associated with procuring and maintaining advanced laboratory analyzers for CMP testing presents a significant challenge, especially for small and mid-sized healthcare providers. High initial capital requirements, coupled with recurring costs for consumables, reagents, and equipment servicing, can limit market penetration in low-resource settings.

In developing regions, many diagnostic facilities lack the financial capacity to upgrade to modern systems capable of performing high-throughput and precise metabolic panel analysis. This disparity in access contributes to inconsistencies in diagnostic availability, delaying early detection and routine monitoring in underserved areas. Addressing cost-related barriers through affordable technology solutions and policy-level interventions remains vital for equitable market expansion.

Key Market Trends

Shift Toward Personalized and Preventive Healthcare

The market is witnessing a strong trend toward personalized and preventive care, with CMP testing playing an increasingly central role. Healthcare providers are leveraging CMP tests to proactively monitor patients for signs of metabolic imbalance, enabling tailored treatment strategies and early intervention.

This trend is supported by advancements in genomics, digital health tools, and AI-driven diagnostics that allow more nuanced interpretation of test results. Employers and insurance providers are also encouraging preventive health screenings through wellness initiatives, further normalizing CMP testing as part of routine healthcare. As healthcare delivery models evolve to prioritize value-based and predictive care, demand for comprehensive metabolic panel testing is set to grow substantially.

Key Market Players

  • Abbott Laboratories
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings Limited
  • Sonic Healthcare Limited
  • Unipath Specialty Laboratory Limited
  • SYNLAB International GmbH
  • ARUP Laboratories
  • Genoptix, Inc.
  • Nova Medical, Inc.
  • Mindray Medical International Limited

Report Scope:

In this report, the Global Comprehensive Metabolic Panel Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Comprehensive Metabolic Panel Testing Market, By Analytes:

  • K+
  • Na+
  • Cl-
  • CO2
  • Glucose
  • BUN
  • Creatinine
  • Ca++
  • Albumin
  • Total protein
  • ALP
  • ALT
  • AST
  • Total bilirubin

Comprehensive Metabolic Panel Testing Market, By Disease:

  • Kidney Disease
  • Liver Disease
  • Diabetes
  • Others

Comprehensive Metabolic Panel Testing Market, By End Use:

  • Laboratory
  • PoC
  • PoC (Instruments)

Comprehensive Metabolic Panel Testing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Comprehensive Metabolic Panel Testing Market.

Available Customizations:

Global Comprehensive Metabolic Panel Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Comprehensive Metabolic Panel Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Analytes (K+, Na+, Cl-, CO2, Glucose, BUN, Creatinine, Ca++, Albumin, Total protein, ALP, ALT, AST, Total bilirubin)
    • 5.2.2. By Disease (Kidney Disease, Liver Disease, Diabetes, Others)
    • 5.2.3. By End Use (Laboratory, PoC, PoC (Instruments))
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Comprehensive Metabolic Panel Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Analytes
    • 6.2.2. By Disease
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Comprehensive Metabolic Panel Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Analytes
        • 6.3.1.2.2. By Disease
        • 6.3.1.2.3. By End Use
    • 6.3.2. Mexico Comprehensive Metabolic Panel Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Analytes
        • 6.3.2.2.2. By Disease
        • 6.3.2.2.3. By End Use
    • 6.3.3. Canada Comprehensive Metabolic Panel Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Analytes
        • 6.3.3.2.2. By Disease
        • 6.3.3.2.3. By End Use

7. Europe Comprehensive Metabolic Panel Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Analytes
    • 7.2.2. By Disease
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Comprehensive Metabolic Panel Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Analytes
        • 7.3.1.2.2. By Disease
        • 7.3.1.2.3. By End Use
    • 7.3.2. Germany Comprehensive Metabolic Panel Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Analytes
        • 7.3.2.2.2. By Disease
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom Comprehensive Metabolic Panel Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Analytes
        • 7.3.3.2.2. By Disease
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy Comprehensive Metabolic Panel Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Analytes
        • 7.3.4.2.2. By Disease
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain Comprehensive Metabolic Panel Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Analytes
        • 7.3.5.2.2. By Disease
        • 7.3.5.2.3. By End Use

8. Asia-Pacific Comprehensive Metabolic Panel Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Analytes
    • 8.2.2. By Disease
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Comprehensive Metabolic Panel Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Analytes
        • 8.3.1.2.2. By Disease
        • 8.3.1.2.3. By End Use
    • 8.3.2. India Comprehensive Metabolic Panel Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Analytes
        • 8.3.2.2.2. By Disease
        • 8.3.2.2.3. By End Use
    • 8.3.3. South Korea Comprehensive Metabolic Panel Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Analytes
        • 8.3.3.2.2. By Disease
        • 8.3.3.2.3. By End Use
    • 8.3.4. Japan Comprehensive Metabolic Panel Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Analytes
        • 8.3.4.2.2. By Disease
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia Comprehensive Metabolic Panel Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Analytes
        • 8.3.5.2.2. By Disease
        • 8.3.5.2.3. By End Use

9. South America Comprehensive Metabolic Panel Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Analytes
    • 9.2.2. By Disease
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Comprehensive Metabolic Panel Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Analytes
        • 9.3.1.2.2. By Disease
        • 9.3.1.2.3. By End Use
    • 9.3.2. Argentina Comprehensive Metabolic Panel Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Analytes
        • 9.3.2.2.2. By Disease
        • 9.3.2.2.3. By End Use
    • 9.3.3. Colombia Comprehensive Metabolic Panel Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Analytes
        • 9.3.3.2.2. By Disease
        • 9.3.3.2.3. By End Use

10. Middle East and Africa Comprehensive Metabolic Panel Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Analytes
    • 10.2.2. By Disease
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Comprehensive Metabolic Panel Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Analytes
        • 10.3.1.2.2. By Disease
        • 10.3.1.2.3. By End Use
    • 10.3.2. Saudi Arabia Comprehensive Metabolic Panel Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Analytes
        • 10.3.2.2.2. By Disease
        • 10.3.2.2.3. By End Use
    • 10.3.3. UAE Comprehensive Metabolic Panel Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Analytes
        • 10.3.3.2.2. By Disease
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Abbott Laboratories
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Quest Diagnostics Incorporated
  • 14.3. Laboratory Corporation of America Holdings Limited
  • 14.4. Sonic Healthcare Limited
  • 14.5. Unipath Specialty Laboratory Limited
  • 14.6. SYNLAB International GmbH
  • 14.7. ARUP Laboratories
  • 14.8. Genoptix, Inc.
  • 14.9. Nova Medical, Inc.
  • 14.10. Mindray Medical International Limited

15. Strategic Recommendations

16. About Us & Disclaimer